Core Viewpoint - Nanjing Pharmaceutical Group Co., Ltd. is set to hold its first extraordinary general meeting of shareholders in 2026 on February 5, 2026, with both on-site and online voting options available [1][2]. Meeting Details - The meeting will take place on February 5, 2026, at 14:00 in Nanjing [1]. - The voting will be conducted through a combination of on-site and online methods using the Shanghai Stock Exchange's voting system [1][2]. - The online voting will be available from 9:15 to 15:00 on the same day [2]. Voting Procedures - Shareholders can vote via the Shanghai Stock Exchange's network voting system, either through a trading terminal or an internet platform [6][7]. - Specific procedures apply for shareholders involved in margin trading, transfer, and other related accounts [3]. Agenda Items - The meeting will review several proposals, including special resolutions and matters requiring separate voting for minority investors [5][6]. - The proposals have been previously approved by the board meetings held on December 18, 2025, and January 19-20, 2026 [5]. Attendance and Registration - Shareholders registered by the close of trading on the registration date are entitled to attend the meeting [11]. - Registration for attendance will occur on February 4, 2026, with specific requirements for both corporate and individual shareholders [12][13]. Additional Services - To facilitate participation, the company will utilize a reminder service to notify shareholders about the meeting and voting options [7].

Group 1 - The core point of the article is that Nanjing Pharmaceutical (600713) has indicated on an interactive platform that its financial shared service center is still in preparation and has not been officially established [1] Group 2 - The company is currently in the process of setting up its financial shared service center, which suggests a focus on improving operational efficiency and financial management in the future [1]

证券代码：600713 证券简称：南京医药 公告编号：ls2026-012 债券代码：110098 债券简称：南药转债 南京医药集团股份有限公司 关于召开2026年第一次临时股东会的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 南京医药集团股份有限公司（以下简称"公司"）于 2026 年 1 月 21 日发布《南 京医药集团股份有限公司关于召开 2026 年第一次临时股东会的通知》，上述公 告已刊登在《中国证券报》《上海证券报》以及上海证券交易所网站 （www.sse.com.cn）。根据相关规定，公司现发布本次股东会的提示性公告如下： 重要内容提示： 股东会召开日期：2026年2月5日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 一、 召开会议的基本情况 (一) 股东会类型和届次 2026年第一次临时股东会 (二) 股东会召集人：董事会 (三) 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相 结合的方式 (四) 现场会议召开的日期、时间和地点 至2026 年 2 月 5 日 1 ...

南京医药集团股份有限公司 2026 年第一次临时股东会材料 2026 年 2 月 5 日 1、审议关于变更回购股份用途并注销的议案； 2、审议关于变更注册资本暨修订《公司章程》部分条款的议案； 3、审议关于公司 2026 年度预计日常关联交易的议案； 4、审议关于修订《南京医药集团股份有限公司独立董事工作制度》的 议案； 目 录 | 南京医药集团股份有限公司 2026 年第一次临时股东会议程 | 2 | | --- | --- | | 议案一：关于变更回购股份用途并注销的议案 | 3 | | 议案二：关于变更注册资本暨修订《公司章程》部分条款的议案 | 7 | | 议案三：关于公司 2026 年度预计日常关联交易的议案 | 9 | | 议案四：关于修订《南京医药集团股份有限公司独立董事工作制度》的议 | | | 案 | 18 | | 议案五：关于修订《南京医药集团股份有限公司累积投票制实施细则》的 | | | 议案 | 34 | 1 南京医药集团股份有限公司 2026 年第一次临时股东会议程 一、介绍参会的嘉宾和股东情况 二、宣读会议审议的议案相关内容 十、会议结束 南京医药集团股份有限公司 2026 年 2 ...

Core Viewpoint - The announcement details the unlocking and listing of 4,476,712 shares from the 2021 restricted stock incentive plan of Nanjing Pharmaceutical Group Co., Ltd, which will be available for trading starting January 30, 2026 [2][4][20]. Group 1: Stock Unlocking Details - The total number of shares to be unlocked is 4,476,712, which represents 0.34% of the company's total share capital [20]. - A total of 324 incentive recipients meet the conditions for unlocking these shares [17][19]. - The unlocking conditions have been met as the third lock-up period has expired, and the company's performance criteria have been achieved [18][19]. Group 2: Incentive Plan Approval and Implementation - The incentive plan was approved by the board on November 29, 2021, and has undergone various procedural steps including public announcements and independent reviews [5][6][7]. - The first grant of restricted stock was registered on January 24, 2022, marking the start of the lock-up periods [18]. - The plan has seen multiple adjustments and reviews, including the repurchase and cancellation of shares from recipients who no longer meet the criteria due to various reasons [9][12][16]. Group 3: Future Implications - The shares will be listed for trading on January 30, 2026, following the completion of the unlocking process [20][21]. - There are specific transfer restrictions for directors and senior management regarding the shares they hold, including limits on annual transfers and conditions post-employment [21][22].

2021 年限制性股票激励计划首次授予部分第三个解除 限售期股票解锁暨上市公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：600713 证券简称：南京医药 公告编号：ls2026-011 债券代码：110098 债券简称：南药转债 南京医药集团股份有限公司 重要内容提示： 本次股票上市类型为股权激励股份；股票认购方式为网下，上市股数为 4,476,712股。 本次股票上市流通总数为4,476,712股。 本次股票上市流通日期为2026 年 1 月 30 日。 南京医药集团股份有限公司（以下简称"公司"）于 2026 年 1 月 19-20 日召开 第十届董事会临时会议，会议审议通过了《关于公司 2021 年限制性股票激励计划 首次授予部分第三个解除限售期解除限售条件成就的议案》。根据公司《2021 年限 制性股票激励计划（草案）》（以下简称"《激励计划》"）、公司《2021 年限制性股 票激励计划管理办法》（以下简称"《激励计划管理办法》"）、公司《2021 年限制性 股票激励计划考核管理办法》（以下简称" ...

Core Viewpoint - On January 26, a total of 8 listed companies will have their restricted shares unlocked, with a total market value of approximately 2.11 billion yuan [1] Summary by Category Restricted Share Unlocking - The companies involved in the unlocking of restricted shares include: - Meili Eco (000010) with 45.48 million shares from equity incentive restrictions - Jiadian Co. (000922) with 236,500 shares from equity incentive restrictions - Nanjing Pharmaceutical (600713) with 5.43 million shares from equity incentive restrictions - Nuofushin (002215) with 4.43 million shares from equity incentive restrictions - Great Wall Motors (601633) with 13.67 million shares from equity incentive restrictions - Xutian Salt Industry (600929) with 513,600 shares from equity incentive restrictions - Tianzheng Electric (605066) with 462,500 shares from equity incentive restrictions - Yifang Bio (688382) with 161 million shares [1]

Core Insights - Jilin Aodong Pharmaceutical Group Co., Ltd. has over 60 years of experience in the traditional Chinese medicine sector, focusing on the unique characteristics of the Changbai Mountain region and combining tradition with innovation to revitalize its brand [1][2] Group 1: Company Background and Development - The company originated from the state-owned Yanbian Dunhua Deer Farm established in 1957, forming a deep connection with local medicinal materials [1] - Jilin Aodong has built the largest GAP-certified deer breeding base in Asia and a medicinal material base in Changbai Mountain, establishing a resource library and database for local medicinal materials [1] - The company aims to become a leading enterprise in northern Chinese medicinal materials through a comprehensive industrial layout, including seedling nurseries and demonstration bases [1] Group 2: Technological Innovation and Quality Control - Jilin Aodong is breaking through traditional bottlenecks in Chinese medicine by integrating modern technology, transitioning from "experience-based manufacturing" to "intelligent manufacturing" [1] - The company has obtained 525 certifications for traditional Chinese medicine formula granules and has established an advanced traceability system for the entire industry chain to ensure medication safety [1][2] Group 3: Financial Strategy and Market Position - The dual-driven model of "healthcare + financial capital" supports the company's long-term strategy and adaptation to industry changes [2] - As the largest shareholder of GF Securities, Jilin Aodong also holds significant stakes in Shanghai Pharmaceuticals, Nanjing Pharmaceutical, and Liaoning Chengda, creating a capital synergy network across finance, pharmaceuticals, retail, and distribution [2] - The financial sector provides stable cash flow that supports the pharmaceutical business, ensuring high-quality development [2] Group 4: Future Outlook - Jilin Aodong plans to continue deepening research on the modernization of traditional Chinese medicine and extending its industrial chain layout [2] - The company aims to integrate into the "Healthy China" initiative, leveraging Changbai Mountain's medicinal materials, technological innovation, and capital collaboration to enhance its brand and contribute to the revitalization of the traditional Chinese medicine industry [2]

Group 1 - The company announced the successful payment of its third phase of super short-term financing bonds for 2025, ensuring the smooth execution of the payment process [1] - The bond payment will be made to the designated account of the bondholders on the payment date, with adjustments for public holidays [1] - The company emphasizes the importance of timely notification for any changes in the fund transfer path by bondholders to avoid delays in receiving funds [1] Group 2 - The company will hold its first extraordinary general meeting of shareholders in 2026 on February 5, 2026, at 14:00 [5] - Voting will be conducted through a combination of on-site and online methods, with specific time slots for online voting [6][7] - The meeting will discuss various resolutions, including special resolutions and those requiring abstention from related shareholders [9] Group 3 - The company has issued a total of 5 billion RMB in super short-term financing bonds in its second phase for 2026, with funds received on January 19, 2026, to be used for working capital and repaying bank loans [24] - The company has previously issued multiple phases of super short-term financing bonds, with the total amount of outstanding bonds yet to mature [22][23] Group 4 - The company has announced the achievement of conditions for the third release of restrictions on its 2021 stock incentive plan, allowing 324 participants to unlock 4.476712 million shares, representing 0.34% of the total share capital [25][36] - The company has followed all necessary procedures and received approvals for the stock incentive plan, ensuring compliance with relevant regulations [36][37] Group 5 - The company has disclosed its expected daily related transactions for 2026, which will exceed 30 million RMB and require shareholder approval due to the amount exceeding 5% of the latest audited net assets [41][43] - The related transactions are deemed necessary for the company's operations and will be conducted at market prices, ensuring no harm to the company's interests [41][51]

证券代码：600713 证券简称：南京医药 编号：ls2026-009 债券代码：110098 债券简称：南药转债 南京医药集团股份有限公司 2026 年度第二期超短期融资券发行结果公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、本次超短期融资券发行审议情况： 南京医药集团股份有限公司（以下简称"公司"）于 2024 年 5 月 31 日召开公 司 2023 年年度股东大会，会议审议通过《关于公司发行超短期融资券的议案》， 同意公司向中国银行间市场交易商协会（以下简称"交易商协会"）申请注册发行 不超过人民币 60 亿元（含）的超短期融资券。 2024 年 10 月 30 日，公司收到交易商协会《接受注册通知书》（中市协注 【2024】SCP335 号），交易商协会决定接受公司超短期融资券注册，注册金额为 人民币 60 亿元，注册额度自通知书落款之日（2024 年 10 月 29 日）起 2 年内有效。 公司在注册有效期内可分期发行超短期融资券。 二、公司前期发行的超短期融资券情况： 公司目前已发行但尚未到期兑付的超 ...